library.onepin.app/cjc-1295-no-dac Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Growth Hormone

Growth Hormone Synthetic GHRH analog Not FDA-approved · investigational

CJC-1295 no DAC

Mod GRF 1-29 · Modified GRF (1-29) · ModGRF1-29

Synthetic GHRH analogModified GRF(1-29)Growth hormone secretagogue29-amino acid peptide with 4 substitutions

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF) is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of endogenous GHRH with four amino acid substitutions (positions 2, 8, 15, 27) that protect against enzymatic degradation while preserving full biological activity at the GHRH receptor. Unlike CJC-1295 with DAC, this variant does NOT contain the Drug Affinity Complex (maleimide linker) that provides albumin binding, resulting in a shorter half-life of approximately 30 minutes versus 6-8 days. This shorter duration preserves natural pulsatile GH release patterns. It is the most commonly paired GHRH analog with Ipamorelin, sold as a pre-mixed blend by many compounding pharmacies.

Quick Start
Route
SubQ injection
Start low
100 mcg per injection
Frequency
1-3 times daily
Timing
Fasted. 2+ hours empty stomach for optimal GH response.

Same fasting rules as Ipamorelin. Administer together with Ipamorelin at bedtime on empty stomach. 2+ hours fasted.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
100 mcg per injection · SubQ injection · 1-3 times daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
100 mcg per injection
1-3 times daily
Standard
Anti-Aging Pulse
100 mcg · SubQ · Daily
anecdotal · community
100 mcg
Daily
Intermediate
Athletic (Multi-Dose)
100 mcg per dose · SubQ · 3x Daily
anecdotal · community
100 mcg per dose
3x Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

CJC-1295 no DAC binds to GHRH receptors on pituitary somatotrophs, activating cAMP/PKA signaling to release stored GH granules. The four amino acid substitutions (Ala2->D-Ala, Asn8->Gln, Ala15->Ala(modified), Met27->Leu) protect against DPP-IV degradation and methionine oxidation. Without the DAC maleimide linker, it does not bind albumin and is cleared rapidly (~30 min half-life), producing a single acute GH pulse that mimics natural pulsatile secretion. When paired with Ipamorelin (ghrelin receptor agonist), the dual GHRH + GHRP stimulation amplifies pulse amplitude and frequency, producing 3-5x greater GH release than either peptide alone.

CJC-1295 no DAC binds to GHRH receptors on pituitary somatotrophs, activating cAMP/PKA signaling to release stored GH granules. The four amino acid substitutions (Ala2->D-Ala, Asn8->Gln, Ala15->Ala(modified), Met27->Leu) protect against DPP-IV degradation and methionine oxidation. Without the DAC maleimide linker, it does not bind albumin and is cleared rapidly (~30 min half-life), producing a single acute GH pulse that mimics natural pulsatile secretion. When paired with Ipamorelin (ghrelin receptor agonist), the dual GHRH + GHRP stimulation amplifies pulse amplitude and frequency, producing 3-5x greater GH release than either peptide alone.

02

What to expect

Early
Days 1–7

Days 1-7: Improved sleep. Mild flushing post-injection. No visible body composition changes yet.

Mid
Weeks 2–4

Weeks 2-6: Recovery improvements. Sleep consistently better. Body comp changes beginning.

Later
Weeks 4–12

Weeks 6-16: Significant body composition changes when paired with Ipamorelin, diet, and training.

03

Evidence

HumanModerate
AnimalPresent
In-vitroPresent
2005Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog · Jette L et al, Endocrinology ↗peer reviewed
2006Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · Teichman SL et al, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed
2006Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog · Ionescu M, Frohman LA, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed
04

The honest take

Pulsatile vs continuous GH

Short half-life (~30 min) preserves natural GH pulsatility, which is considered superior to continuous GH elevation for body composition and health. This is its advantage over CJC-1295 with DAC.

Most popular GH peptide stack

CJC no DAC + Ipamorelin is the most widely used GH peptide combination in the community. Sold pre-mixed by numerous compounding pharmacies.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

BPC-157BPC upregulates GH receptors, amplifying CJC effects
VIPNo chemical conflict. Complementary pathways.
GHRP-2GHRH + GHRP synergy
GHRP-6GHRH + GHRP synergy

Keep separate

TesamorelinSame GHRH receptor target. Redundant stimulation with no added benefit.
CJC-1295 with DACDo not run both CJC variants simultaneously.
06

Side effects & safety

Commonly reported

  • Transient flushing post-injection
  • Mild water retention first 1-2 weeks
  • Occasional headache

Less common & notes

  • Joint stiffness from GH/IGF-1 elevation.
  • Monitor fasting glucose.
  • Contraindicated in active malignancy.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
0.5h
Peak · Tmax
0.25h
Elimination
2.5h
Activity
2-3 hours (acute GH pulse; GH/IGF-1 elevation lasts several hours post-injection)

Storage. Shorter stability than most peptides. Use within 14-21 days after reconstitution. DPP-IV degradation continues in solution despite amino acid substitutions. Refrigerate 2-8C. This shelf life becomes limiting factor for CJC/Ipa pre-mixed blends.

08

Regulatory status

Not FDA-approved. WADA prohibited under S2. Available through compounding and research channels.

Put it to work

Calculate, log & track

Open CJC-1295 no DAC straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open CJC-1295 no DAC in the app →

Go deeper

The guide & community

The complete CJC-1295 no DAC walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community